Wellington Management Group LLP Has $1.32 Million Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Wellington Management Group LLP boosted its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 4.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 94,859 shares of the company’s stock after buying an additional 4,034 shares during the quarter. Wellington Management Group LLP’s holdings in Tyra Biosciences were worth $1,319,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Alta Partners Management Company L.P. acquired a new stake in Tyra Biosciences during the 4th quarter valued at approximately $56,716,000. Pictet Asset Management Holding SA bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at $4,921,000. Raymond James Financial Inc. acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth $761,000. Victory Capital Management Inc. raised its stake in Tyra Biosciences by 88.3% during the fourth quarter. Victory Capital Management Inc. now owns 56,640 shares of the company’s stock worth $787,000 after buying an additional 26,560 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Tyra Biosciences in the third quarter valued at $593,000. Institutional investors own 84.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on TYRA shares. UBS Group assumed coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $30.83.

Insider Activity

In related news, Director Nina S. Kjellson sold 3,993 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the transaction, the director now owns 3,707,420 shares of the company’s stock, valued at approximately $60,653,391.20. This trade represents a 0.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 21,998 shares of company stock worth $344,818 over the last three months. 15.40% of the stock is currently owned by insiders.

Tyra Biosciences Stock Performance

Shares of NASDAQ:TYRA opened at $7.96 on Monday. The firm has a market cap of $422.60 million, a P/E ratio of -4.94 and a beta of 1.19. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $29.60. The business’s 50 day simple moving average is $10.73 and its two-hundred day simple moving average is $15.11.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05. On average, equities analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.